Haussier
Pfizer's Q2 2026 earnings beat expectations, stock holds gains near $28.
Ce briefing n’est pas encore disponible dans cette langue — version anglaise affichée.
Pfizer's stock remains strong following a Q2 2026 earnings report that exceeded analyst expectations and a raised full-year guidance. The company's focus on oncology projects and institutional investor interest contribute to the positive sentiment.
Points clés
- Q2 2026 earnings beat expectations with a 3% revenue increase to $15.034 billion.
- Pfizer raised its full-year 2026 guidance, targeting an EPS between $2.80 and $3.00.
- Institutional investors, including Bank of New York Mellon, hold significant positions in Pfizer, indicating confidence in the company's prospects.
- Pfizer's oncology portfolio, notably the breast cancer drug Ibrance, continues to be a key focus for future growth.
Sources
Généré par IA à partir de sources d'actualités publiques. Ceci n'est pas un conseil financier.
